Key result
T3 replacement restores cardiac gene expression in hypothyroidism, suggesting potential benefit in heart failure.
Answers are grounded in this paper and cite their sources.
The effects of hypothyroidism on the cardiovascular system have been the subject of much research over the last several decades. The hypothyroid cardiac phenotype includes impaired contractile function, decreased cardiac output, and alterations in myocyte gene expression. In the setting of cardiac disease, as in other acute illnesses, alterations in thyroid hormone metabolism occur that result in decreased serum triiodothyronine (T(3)) levels. This is referred to as low T(3) syndrome. Similarities between the heart failure phenotype and the hypothyroid cardiac phenotype are numerous including changes in the expression of thyroid hormone regulated myocyte specific genes. The heart responds in a very sensitive manner to reduced circulating levels of T(3) with decreased expression of positively regulated genes and increased expression of negatively regulated genes. In the present paper we review data on thyroid hormone mediated cardiac specific gene transcriptional regulation. T(3) replacement therapy for hypothyroidism restores normal expression of these T(3) regulated genes and recent experiments suggest that the diseased human heart in congestive failure would benefit from similar T(3) replacement therapy.
No takes yet. Share an insight, caveat, or question.
Danzi et al. (2002) conducted a review in Cardiovascular disease, hypothyroidism, and heart failure. Triiodothyronine (T3) replacement therapy was evaluated. Triiodothyronine (T3) replacement therapy restores normal expression of T3-regulated genes in hypothyroidism, suggesting a potential benefit for patients with congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: